Topical Tofacitinib for Atopic Dermatitis – Outcomes from Randomized Phase 3 Clinical Trial: First Approval

Authors

Alok Chaturvedi (ORCID: https://orcid.org/0000-0003-4666-0197)
Hemant Zaveri (ORCID: https://orcid.org/0000-0002-3104-2698)
Dev Patel (ORCID: https://orcid.org/0000-0003-0581-3572)

Institutions

Intas Pharmaceuticals (India) (IN)

Publication Details

Journal: Indian Journal of Dermatology
Published: 2025-10-08
DOI: https://doi.org/10.4103/ijd.ijd_197_24
Primary Topic: Dermatology and Skin Diseases
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Topical Tofacitinib for Atopic Dermatitis – Outcomes from Randomized Phase 3 Clinical Trial: First Approval

Alok Chaturvedi, Hemant Zaveri, Dev Patel

Oct 8, 2025

Indian Journal of Dermatology

Dermatology and Skin Diseases

article

Topical Tofacitinib for Atopic Dermatitis – Outcomes from Randomized Phase 3 Clinical Trial: First Approval

Alok Chaturvedi, Hemant Zaveri, Dev Patel

October 8, 2025article en

Abstract

No abstract available for this paper.

Indian Journal of DermatologyVol. 71(1)

Intas Pharmaceuticals (India) (IN)

Openalex Percentile: Top 52%

Dermatology and Skin Diseases

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Topical Tofacitinib for Atopic Dermatitis – Outcomes from Randomized Phase 3 Clinical Trial: First Approval — Alok Chaturvedi, Hemant Zaveri, et al. · Indian Journal of Dermatology (2025) | TGRS Research Map | TGRS